Friday, May 27, 2022
Stop Diabetes
No Result
View All Result
  • Home
  • Diabetes
  • Diabetic Lifestyle
  • The Best Habits
  • Reversing Diabetes
  • Diabetes Nutrition
  • Shop
  • Contact Us
No Result
View All Result
  • Home
  • Diabetes
  • Diabetic Lifestyle
  • The Best Habits
  • Reversing Diabetes
  • Diabetes Nutrition
  • Shop
  • Contact Us
No Result
View All Result
Stop Diabetes
No Result
View All Result
Home Diabetes Alternative Therapies for Diabetes Reversing Diabetes

Enterin Announces Appointment of Donald Munoz to Its Board of Directors

diabetes-admin by diabetes-admin
April 7, 2021
in Reversing Diabetes
0
Enterin Announces Appointment of Donald Munoz to Its Board of Directors
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter


PHILADELPHIA, April 7, 2021 /PRNewswire/ — Enterin, Inc., a clinical-stage biopharmaceutical firm pioneering novel remedies for neurodegenerative illnesses, pronounces the appointment of Donald Munoz to its Board of Administrators.

“We’re thrilled to welcome Don to Enterin’s Board,” stated David McCullough, Enterin’s Chief Government Officer. “He brings important biotechnology trade experience and super monetary expertise given his roles as a public-company CFO and healthcare funding banker. Don can be an excellent companion to the manager staff as Enterin enters its subsequent section of progress.”

READ ALSO

Tommy Mallet reveals he is ‘fighting’ to get in shape after receiving pre diabetic diagnosis

Industry lobbying on WHO overshadowing public

Enterin’s Board Chairman Jay Brammer added, “We stay up for working with Don and I’m assured he’ll make sturdy contributions to the success of Enterin.”

“I’m excited to hitch Enterin’s Board and work with the staff to advance our compounds by way of medical improvement,” stated Don Munoz. “Enterin’s compounds signify a novel and extremely promising strategy towards the therapy of neurodegenerative illnesses, and I stay up for contributing to the Firm’s success.”

Munoz presently serves as Chief Monetary Officer of NuCana plc, a Nasdaq-listed biotechnology firm targeted on considerably enhancing therapy outcomes for sufferers with most cancers. NuCana accomplished a $114 million IPO in 2017 and an $80 million follow-on providing in 2020. Previous to becoming a member of NuCana in 2015, Don served as Group Chief Monetary Officer of NOXXON Pharma. He has an in depth monetary background with roughly 20 years as a healthcare funding banker at Alex. Brown & Sons, Deutsche Financial institution, Leerink Companions and Cowen. Don has accomplished over 100 financing and merger and acquisition transactions with an mixture worth of greater than $30 billion. He acquired an MBA in Finance and Accounting from Columbia Enterprise Faculty, the place he was elected to Beta Gamma Sigma, and an AB in Psychology from Dartmouth Faculty.

About Enterin
Enterin is growing novel compounds that restore the dysfunctional gut-brain axis to deal with sufferers with neurodegenerative illnesses. Enterin is pioneering the medical neighborhood’s understanding of the hyperlink between infections, dysfunction of the enteric nervous system (ENS) and the early signs and development of neurodegenerative illnesses. Enterin’s lead compound, ENT-01, has been proven to displace membrane-bound alpha-synuclein (αS) aggregates from nerve cells within the ENS and enhance neural signaling between the intestine and the mind in preclinical fashions of Parkinson’s illness and in human research. ENT-01 is presently in a 150-patient, placebo-controlled Part IIb medical research designed to display its potential to reverse the neurological signs of Parkinson’s illness. Enterin’s second compound, ENT-03, is designed to reverse central insulin resistance, a key pathology in illnesses similar to weight problems, diabetes, and Alzheimer’s illness. ENT-03 is predicted to enter a Part I research in 2022.

For extra info, please go to www.enterininc.com.

Contact
Enterin Inc.
[email protected]

Associated Photos

enterin-logo.jpg
Enterin Emblem
Enterin Emblem

SOURCE Enterin Inc.

Enterin Announces Appointment of Donald Munoz to Its Board of Directors



Source link

Tags: announcesappointmentBoardDirectorsDonaldEnterinMunoz

Related Posts

Tommy Mallet reveals he is ‘fighting’ to get in shape after receiving pre diabetic diagnosis
Reversing Diabetes

Tommy Mallet reveals he is ‘fighting’ to get in shape after receiving pre diabetic diagnosis

May 19, 2022
Reversing Diabetes

Industry lobbying on WHO overshadowing public

May 19, 2022
Understanding how the process starts can point to new directions in aging research — ScienceDaily
Reversing Diabetes

Understanding how the process starts can point to new directions in aging research — ScienceDaily

May 19, 2022
The Importance of Recognizing a Stroke
Reversing Diabetes

The Importance of Recognizing a Stroke

May 18, 2022
Importance of Microbiome, Disease Prevention Among Topics to Be Discussed at DDW 2022
Reversing Diabetes

Importance of Microbiome, Disease Prevention Among Topics to Be Discussed at DDW 2022

May 18, 2022
Scientists Are Developing Patch That Warns of Oncoming Drug Overdose – Consumer Health News
Reversing Diabetes

Scientists Are Developing Patch That Warns of Oncoming Drug Overdose – Consumer Health News

May 18, 2022

POPULAR NEWS

Glucofort Reviews (Warning) Fake Results or Real Ingredients?

Glucofort Reviews (Warning) Fake Results or Real Ingredients?

July 31, 2021
Fruit Street Health launches employer advisory board to manage healthcare costs with digital health

Fruit Street Health launches employer advisory board to manage healthcare costs with digital health

March 30, 2021
GlucoFreeze Reviews: Shocking Scam Complaints to Know About?

GlucoFreeze Reviews: Shocking Scam Complaints to Know About?

August 11, 2021
Glucofort Reviews (UPDATED) Scam Reports or Real Customer Success Stories?

Glucofort Reviews (UPDATED) Scam Reports or Real Customer Success Stories?

May 14, 2021
Disabled People Deserve A Hot Girl Summer, Too

Disabled People Deserve A Hot Girl Summer, Too

July 23, 2021

EDITOR'S PICK

Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME)

Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME)

May 9, 2022
Potential Parkinson’s Risks Found Years Before Diagnosis : Neurology Today

Potential Parkinson’s Risks Found Years Before Diagnosis : Neurology Today

May 5, 2022
Put your money where your mouth is

Put your money where your mouth is

January 30, 2022
An analysis of risk factors and symptom presentation among groups at risk for SARS-CoV-2 infection

An analysis of risk factors and symptom presentation among groups at risk for SARS-CoV-2 infection

December 7, 2021

Recent Posts

  • Just a Small Amount of Protein Supplement Helps Control Type 2 Diabetes
  • Good diet, physical fitness should be central to national culture
  • Importance of patient and family engagement, the needs for s | DMSO
  • Volunteers sought for trial to develop potential new treatments for Diabetic Neuropathic Pain
  • Disseminated Nocardia paucivorans Infection Resembling Metastatic Disease in a Kidney Transplant Recipient

Categories

  • Alternative Therapies for Diabetes
  • Diabetes
  • Diabetes
  • Diabetes Education
  • Diabetes Nutrition
  • Diabetes Tips
  • Diabetes Types
  • Diabetes Videos
  • Diabetic Insurance
  • Diabetic Lifestyle
  • Diabetic Medication
  • Diabetic Shop
  • Diabetic Specialists – Doctors
  • Prediabetes
  • Reversing Diabetes
  • Sports
  • Symptoms
  • The Best Habits

Follow us

Contact Us

  • Privacy & Policy
  • About Us
  • Contact Us

© 2021 Stop Diabetes

No Result
View All Result
  • Home
  • Diabetes
  • Diabetic Lifestyle
  • The Best Habits
  • Reversing Diabetes
  • Diabetes Nutrition
  • Shop
  • Contact Us

© 2021 Stop Diabetes

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?